Federal Medical Centre, Owo Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2019
NCT03944317
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Federal Medical Centre, Owo | FMCO

Active Ingredients

Drugs in Phase 2 Trials (2)

favipiravir (1 trial)

ribavirin (virazole) (1 trial)

Drugs in Other Trials (2)

azithromycin (zithromax) (1 trial)

sulfadoxine (1 trial)

Indications

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 4